Makarim Shteiwi Abed1, Haider Rehman Alwan2, Jaleel Najah Jaleel3
1Salahdin Health Directorate /Higher Health Institute, Tikrit
2Diala Health Directorate Public Health laboratory, Baquba
3College of Health and Medical Techniques, Middle Technical University, Baghdad, Iraq
(✉) Corresponding Author: fi72523@gmail.com
Received: July 28, 2022/ Revised: Aug 20, 2022/ Accepted: Aug 23, 2022
Abstract
The kidneys’ ability to operate declines slowly and creatively as a result of chronic renal disease. It frequently results from issues with other serious medical disorders (such as spinal cord defects, hypertension, and diabetes). Due to the increased chances of acquiring end-stage renal disease (ESRD) patients, there is a higher incidence of multidrug-resistant organisms in the community, primarily methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). It is also poorly understood how gram-negative bacteria that produce carbapenemase affect ESRD patients on RRT (replacement renal treatment). 39 patients with urinary tract infections and renal failure participated in this study to determine the prevalence of gram-negative bacteria and Enterobacteriaceae that produce carbapenemase in Tiktit city. Disc diffusion method was used to determine whether the isolated and cultured bacteria were carbaqpenemase producing. According to the present study prevalence of carbapenemase producing group among renal failure patient with UTI was (78%), and not carbapenemase group was 22%. The females percentage was 40.6 % and male’s percentage was 37.5%, recurrent UTI infections history for; renal failure patients was very high 73% and in males 40% more than females 34%.
Keywords: Renal Failure, Carpapenemase Producing Bacteria, Recurrent
References
Aswani, S. M., Chandrashekar, U. K., Shivashankara, K. N., & Pruthvi, B. C. (2014). Clinical profile of urinary tract infections in diabetics and non-diabetics. The Australasian medical journal, 7(1), 29.
Ataei, N., Hosseini, M., Baikpour, M., Ataei, F., Bloori Jirandeh, H., Bazargani, B., & Abbasi, A. (2016). Etiology and outcome of chronic kidney disease in iranian children. Int J Pediatr, 4(7), 2105-12.
Bleumin, D., Cohen, M. J., Moranne, O., Esnault, V. L., Benenson, S., Paltiel, O., & Haviv, Y. S. (2012). Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in hemodialysis patients. Journal of Infection, 65(4), 318-325.
Eilertson, B., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., Kaye, K. S., Evans, S. and Fowler, Jr. V. G. (2017). Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. In Open forum infectious diseases, US: Oxford University Press. 4, No. 4, p. ofx216).
Fram, D., Taminato, M., Ponzio, V., Manfredi, S. R., Grothe, C., Batista, R. E. A., & Barbosa, D. (2014). Risk factors for morbidity and mortality of bloodstream infection in patients undergoing hemodialysis: a nested case–control study. BMC research notes, 7(1), 1-8.
Hauck, C., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., & Group, A. R. L. (2016). Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clinical Microbiology and Infection, 22(6), 513-519.
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs, F. R. (2016). Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PloS one, 11(7), e0158765.
Hussein, K., Raz-Pasteur, A., Finkelstein, R., Neuberger, A., Shachor-Meyouhas, Y., Oren, I., & Kassis, I. (2013). Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. Journal of Hospital Infection, 83(4), 307-313.
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., & Yang, C. W. (2013). Chronic kidney disease: global dimension and perspectives. The Lancet, 382(9888), 260-272.
Kato, S., Chmielewski, M., Honda, H., Pecoits-Filho, R., Matsuo, S., Yuzawa, Y. & Lindholm, B. (2008). Aspects of immune dysfunction in end-stage renal disease. Clinical Journal of the American Society of Nephrology, 3(5), 1526-1533.
Leblebicioglu, H., Bodur, H., Dokuzoguz, B., Elaldi, N., Guner, R., Koksal, I., … & Senturk, G. C. (2012). Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever. Vector-Borne and Zoonotic Diseases, 12(9), 805-811.
Levey, A. S., Eckardt, K. U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J. & Eknoyan, G. (2005). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international, 67(6), 2089-2100.
Maggi, P., Bartolozzi, D., Bonfanti, P., Calza, L., Cherubini, C., Di Biagio, A., & Vescini, F. (2012). Renal complications in HIV disease: between present and future.
Melzer, M., Santhakumaran, T., & Welch, C. (2016). The characteristics and outcome of bacteraemia in renal transplant recipients and non-transplant renal patients. Infection, 44(5), 617-622.
O’Donnell, J. N., Miglis, C. M., Lee, J. Y., Tuvell, M., Lertharakul, T., & Scheetz, M. H. (2016). Carbapenem susceptibility breakpoints, clinical implications with the moving target. Expert review of anti-infective therapy, 14(4), 389-401.
Pant, C., Deshpande, A., Anderson, M. P., & Sferra, T. J. (2012). Clostridium difficile infection is associated with poor outcomes in end-stage renal disease. Journal of Investigative Medicine, 60(2), 529-532.
Pharmaceutical, O. M. (2007). Doribax (doripenem) package insert. Raritan (NJ): Ortho-McNeil Pharmaceutical.
Pontillo, C., & Mischak, H. (2016). Urinary biomarkers to predict CKD: is the future in multi-marker panels?. Nephrology Dialysis Transplantation, 31(9), 1373-1375.
Reznichenko, A., Böger, C. A., Snieder, H., van den Born, J., de Borst, M. H., Damman, J., & Navis, G. (2012). UMOD as a susceptibility gene for end-stage renal disease. BMC medical genetics, 13(1), 1-6.
Rojas, L., Muñoz, P., Kestler, M., Arroyo, D., Guembe, M., Rodríguez-Créixems, M., & Bouza, E. (2013). Bloodstream infections in patients with kidney disease: risk factors for poor outcome and mortality. Journal of Hospital Infection, 85(3), 196-205.
Schmidt, G. (2016). Private sector involvement in times of armed conflict: What are the constraints for trading medical equipment?. Journal of Emergency Management, 14(6), 413-421.
Shafi, T., Jaar, B. G., Plantinga, L. C., Fink, N. E., Sadler, J. H., Parekh, R. S., & Coresh, J. (2010). Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. American Journal of Kidney Diseases, 56(2), 348-358.
Surel, U., Niemirowicz, K., Marzec, M., Savage, P. B., & Bucki, R. (2014). Ceragenins–a new weapon to fight multidrug resistant bacterial infections. Medical Studies/Studia Medyczne, 30(3), 207-213.
Vading, M. (2016). Klebsiella pneumoniae and Escherichia coli: multidrug- re4istance and different aspects of invasive infections. Inst för laboratoriemedicin/Dept of Laboratory Medicine.
Vaziri, N. D., Wong, J., Pahl, M., Piceno, Y. M., Yuan, J., DeSantis, T. Z., & Andersen, G. L. (2013). Chronic kidney disease alters intestinal microbial flora. Kidney international, 83(2), 308-315.
How to cite this article
Abed, M. S., Alwan, H. R., Jaleel, N. J. (2022). Prevalence of carbapenemase producing gram-negative bacteria in renal failure urinary tract infection patients in tikrit city, Iraq. Science Archives, Vol. 3 (3), 195-199. https://doi.org/10.47587/SA.2022.3307
License Article Metadata
This work is licensed under a Creative Commons Attribution 4.0 International License.
